The North America Live Biotherapeutic Products And Microbiome CDMO Market would witness market growth of 41.7% CAGR during the forecast period (2023-2029).
Living organisms, like viruses or bacteria, are utilized in live biotherapeutic products to cure or prevent disease. The US FDA describes live biotherapeutic products as biological products that are live organism-containing, such as bacteria. LBPs should be applicable to the prevention, cure, or treatment of a human disease or condition and should not be a vaccine. LBPs are not oncolytic bacteria, filterable viruses, or products designed to be gene therapy agents. They are also not supplied via injection. For example, an LBP might be a strain or strain of lactobacilli given orally to individuals with ulcerative colitis or given intravaginally in order to avoid bacterial vaginosis. Recombinant LBPs are live biotherapeutic products made of microorganisms that have undergone genetic mutation, such as the deliberate insertion, deletion, or alteration of genetic information.
A deeper knowledge of the significance of microbes in maintaining and sustaining critical physiological processes of the host has emerged in biomedical science during the last several decades, changing the perspective from one in which all microorganisms are viewed as health hazards. On the contrary, the microbiome is crucial for human health, and changes to its composition, relative abundances, or elements can result in disease. This is now a well-accepted fact. Therefore, it is crucial to comprehend this microbiome-host link in order to affect the microbiome with the goal of maintaining or enhancing health. Furthermore, the discovery of novel microbial strains and/or microbial functions helpful in the development of future preventative or therapeutic applications has been made possible by large-scale research efforts like Meta Hit and the Human Microbiome Project.
The region also has a high prevalence of C.difficile. Major health risks are posed by C. diff. 12,800 fatalities and an estimated 223,900 hospitalized patient cases were reported in the United States in 2017, as reported by the CDC. The advent of the infectious strain ribotype 027 was a major factor in the rise in Clostridioides difficile infection and related hospitalizations in the 2000s. The development of improved diagnostic tests for C. difficile in the latter half of the early 2000s, like nucleic acid amplification tests (NAATs), is most likely to blame for the increase in the frequency of infections that are caused by C. difficile. Consequently, government-initiated R&D and monitoring programs have increased in the region. Hence, the region presents lucrative growth prospects for the regional market throughout the forecast period.
The US market dominated the North America Live Biotherapeutic Products And Microbiome CDMO Market by Country in 2022, thereby, achieving a market value of $80,668.6 Thousands by 2029. The Canada market is showcasing a CAGR of 44.9% during (2023 - 2029). Additionally, The Mexico market would register a CAGR of 43.6% during (2023 - 2029).
Based on Application, the market is segmented into C.difficile, Crohns Disease, IBS, Diabetes, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Live Biotherapeutic Products And Microbiome CDMO Market is Projected to reach USD 159.1 Million by 2029, at a CAGR of 42.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB), Cerbios-Pharma SA, Biose Industrie, List Biological Laboratories, Inc., AcuraBio Pty Ltd (Ampersand Capital Partners), Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH), Quay Pharmaceuticals Ltd (SGS S.A.), BiomX, Inc., Lonza Group AG, and 4D Pharma Plc.
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 